ethyl-4-(cyclopropanecarbonyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl-4-(cyclopropanecarbonyl)piperazine
• 英文别名: Cyclopropyl(4-ethylpiperazin-1-yl)methanone；cyclopropyl-(4-ethylpiperazin-1-yl)methanone
• 化学式: C₁₀H₁₈N₂O
• mdl: MFCD03397166
• 分子量: 182.266
• InChiKey: IHZRTGDQLTTXRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-乙基哌嗪 、 环丙甲酸 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 ethyl-4-(cyclopropanecarbonyl)piperazine
  参考文献：
  名称：

  Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

  摘要：

  A series of adamantyl amide 11 beta-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11 beta-HSD1 over 11 beta-HSD2 and possess excellent cellular potency in human and murine 11 beta-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.057

文献信息

• [EN] INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE<br/>[FR] INHIBITEURS DU RÉCEPTEUR ALK (« ACTIVIN RECEPTOR-LIKE KINASE »)
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2017181117A1

  公开（公告）日：2017-10-19

  Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  本文描述了抑制ALK2及其突变体的化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物的方法。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• ARYL SULTAM DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20150197529A1

  公开（公告）日：2015-07-16

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, W, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  化合物的公式I：或其药学上可接受的盐，其中m、n、p、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗炎症性疾病如关节炎。
• [EN] SUBSTITUTED HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2017207534A1

  公开（公告）日：2017-12-07

  The present invention covers substituted heteroarylbenzimidazole compounds of general formula (I) : in which R1, R2, R3, R4, R5, R6a and R6b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的取代杂环芳基苯并咪唑化合物：其中R1、R2、R3、R4、R5、R6a和R6b如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及用于制造治疗或预防疾病的药物组合物的所述化合物的用途，特别是治疗或预防高增殖和/或炎症性疾病的疾病，作为唯一药剂或与其他活性成分组合使用。
• ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：Li Xiaoming

  公开号：US20080194545A1

  公开（公告）日：2008-08-14

  The present invention is directed to compounds of formula I, pharmaceutical compositions comprising the compounds, and methods for making and using the inventive compounds.

  本发明涉及式I的化合物，包括该化合物的药物组合物，以及制备和使用该创新化合物的方法。